Results 161 to 170 of about 718,683 (284)

Case Report: Personalized therapy in gynecological neuroendocrine neoplasm: a case of BRCA2-mutated ovarian neuroendocrine carcinoma treated with PARP-inhibitor. [PDF]

Front Oncol
Mantiero M, Polignano M, Bassetti A, Oldani S, Serino R, Russo A, Villa C, Ducceschi M, Raspagliesi F.   +8 more
europepmc   +1 more source

Phytochemicals as Multitarget Therapeutics in Pancreatic Cancer: Mechanisms, Clinical Evidence, and Translational Challenges

Phytotherapy Research, EarlyView.
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, is aggressive and often diagnosed late, making treatment challenging. This review highlights the potential of phytochemicals, such as curcumin and quercetin, as multitarget agents that influence key carcinogenic pathways. These compounds exhibit anticancer effects by inhibiting processes
Md. Rezaul Islam, Abdur Rauf, F. M. Shourav, Hanan A. Ogaly, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Kamala Badalova, Marcello Iriti   +7 more
wiley   +1 more source

A transcriptomic-based model associated with PARP inhibitor sensitivity and immunogenic signatures in ovarian cancer. [PDF]

Discov Oncol
Sun X, Li C, Wang Z, Geng J, Wang W, Deng K, Xu Z, Zhao H, Huang D.   +8 more
europepmc   +1 more source

Ruta graveolens L. in Evidence‐Based Phytotherapy: Pharmacological Activities, Bioactive Compounds and Safety

Phytotherapy Research, EarlyView.
Graphical representation of ethnomedical uses, major bioactive compounds, pharmacological potential and toxicological risks of Ruta graveolens L. ABSTRACT Ruta graveolens L. is widely used in traditional European, Asian, African, and South American medicine for digestive, nervous, cardiovascular, respiratory, and reproductive disorders.
Tetiana Serhiienko, Victoriya Georgiyants, Liudas Ivanauskas, Olha Mykhailenko   +3 more
wiley   +1 more source

From Oxidative Stress to Bioenergetic Remodeling: Translational Value and Clinical Implications of Exogenous ATP in PARP Inhibitor-Associated Liver Injury [Letter]. [PDF]

Drug Des Devel Ther
Shang M, Ge X.
europepmc   +1 more source

Carbon dots as a smart nanoplatform for the blood‐brain barrier penetration and ischemic stroke therapy

Responsive Materials, EarlyView.
This review presents the structure and transport routes of the blood‐brain barrier, summarizes the ischemic stroke pathophysiological cascade, and discusses the BBB‐crossing mechanisms and multitarget therapeutic effects of carbon dots, demonstrating their promising theranostic potential for ischemic stroke.
Yanhan Huang, Xuan Hou, Haiping Zhao, Qi Kong, Xiayan Wang, Xiaokun Geng, Zaicheng Sun   +6 more
wiley   +1 more source

Mechanisms of PARP Inhibitor Resistance: From Replication Gap Biology and Transcription-Replication Conflicts to PROTAC-Based Next-Generation Strategies. [PDF]

Environ Mol Mutagen
Abinawanto, Sophian A.
europepmc   +1 more source

A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy

Smart Molecules, EarlyView.
A cascade‐responsive small‐molecule prodrug (DHU‐NO3) sequentially releases methylene blue (triggered by reactive oxygen species) and nitric oxide (controlled by 405 nm light), enabling precise spatiotemporal coordination of photodynamic therapy and NO gas therapy to effectively inhibit MYC‐amplified osteosarcoma growth.
Shuxin Peng, Jiangpeng Wu, Shasha Wang, Ying Gao, Xuran Guo, Mengpan Li, Youjin Wu, Yun Wang, Zhengdong Cai, Yingqi Hua, Peng Wei, Yinghua Gao, Tao Yi   +12 more
wiley   +1 more source

Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice. [PDF]

Br J Cancer
Macdonald CJ, McWhirter A, Vaidyanathan A, Ferguson MJ, Eberl HC, Stronach EA, Sawers L, Smith G.   +7 more
europepmc   +1 more source

Differentiating high‐ and low‐grade serous ovarian carcinoma using radiomics: a pilot study

Ultrasound in Obstetrics &Gynecology, EarlyView.
ABSTRACT Objective To identify ultrasound‐based radiomics features capable of distinguishing between high‐grade serous ovarian carcinomas (HGSC) and invasive low‐grade serous ovarian carcinomas (LGSC), and to develop machine‐learning models that include radiomics features to discriminate between the two.
F. Ciccarone, G. Zinicola, E. H. Tran, G. Baldassari, E. Boccia, C. Nero, F. Moro, T. Pasciuto, G. Scambia, G. Ferrandina, A. Fagotti, A. C. Testa, D. Lorusso, Collaborators, F. Borella, F. Buonomo, R. Fruscio, F. Pozzati   +17 more
wiley   +1 more source